Abstract

Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage 3 or 4a, stage 4b or recurrent endometrial cancer: The phase 3, NRG GY018 study (LBA 10)

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call